PELTHOS THERAPEUTICS INC (PTHS) Stock Price & Overview
NYSEARCA:PTHS • US1711262048
Current stock price
The current stock price of PTHS is 20.4 USD. Today PTHS is down by -4.23%. In the past month the price decreased by -11.34%.
PTHS Key Statistics
- Market Cap
- 66.096M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- N/A
- Dividend Yield
- N/A
PTHS Stock Performance
PTHS Stock Chart
PTHS Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to PTHS.
PTHS Earnings
On March 19, 2026 PTHS reported an EPS of -2.03 and a revenue of 9.39M. The company beat EPS expectations (51.81% surprise) and beat revenue expectations (1.26% surprise).
PTHS Forecast & Estimates
12 analysts have analysed PTHS and the average price target is 59.5 USD. This implies a price increase of 191.67% is expected in the next year compared to the current price of 20.4.
PTHS Groups
Sector & Classification
PTHS Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PTHS Ownership
PTHS Latest News, Press Relases and Analysis
PTHS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PTHS
Company Profile
Pelthos Therapeutics, Inc. engages in the provision of therapeutic products. The company is headquartered in Durham, North Carolina and currently employs 4 full-time employees. The company went IPO on 2024-02-16. The firm's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. In addition to ZELSUVMI, the Company has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL. The Company’s product Xepi is a quinolone antimicrobial indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients two months of age and older. Its NaV 1.7 is a clinical-stage assets which selectively target the sodium ion-channel. The firm also Xeglyze, which is a is a pediculicide indicated for the topical treatment of head lice infestation in patients six months of age and older.
Company Info
IPO: 2024-02-16
PELTHOS THERAPEUTICS INC
4020 Stirrup Creek Drive, Suite 110
Durham NORTH CAROLINA US
Employees: 4
Phone: 19199082422
PELTHOS THERAPEUTICS INC / PTHS FAQ
What does PELTHOS THERAPEUTICS INC do?
Pelthos Therapeutics, Inc. engages in the provision of therapeutic products. The company is headquartered in Durham, North Carolina and currently employs 4 full-time employees. The company went IPO on 2024-02-16. The firm's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. In addition to ZELSUVMI, the Company has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL. The Company’s product Xepi is a quinolone antimicrobial indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients two months of age and older. Its NaV 1.7 is a clinical-stage assets which selectively target the sodium ion-channel. The firm also Xeglyze, which is a is a pediculicide indicated for the topical treatment of head lice infestation in patients six months of age and older.
What is the stock price of PELTHOS THERAPEUTICS INC today?
The current stock price of PTHS is 20.4 USD. The price decreased by -4.23% in the last trading session.
What is the dividend status of PELTHOS THERAPEUTICS INC?
PTHS does not pay a dividend.
What is the ChartMill rating of PELTHOS THERAPEUTICS INC stock?
PTHS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the GICS sector and industry of PTHS stock?
PELTHOS THERAPEUTICS INC (PTHS) operates in the Health Care sector and the Biotechnology industry.
Can you provide the market cap for PELTHOS THERAPEUTICS INC?
PELTHOS THERAPEUTICS INC (PTHS) has a market capitalization of 66.10M USD. This makes PTHS a Micro Cap stock.
Can you provide the short interest for PTHS stock?
The outstanding short interest for PELTHOS THERAPEUTICS INC (PTHS) is 5.32% of its float.